Related Experiment Video
Updated: Jul 7, 2026
One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance
Deborah C Draghi1, Stacy Tench, Michael J Dowzicky
1Eurofins Medinet, Inc., Herndon, VA 20171, USA.
Abstract:
Tigecycline is the first clinically available semisynthetic glycylcycline approved for clinical use. This study was done to establish a baseline for ongoing surveillance of tigecycline's activity as this agent's clinical use increases. Against 1,796 Staphylococcus aureus (559 multidrug resistant), tigecycline had the lowest minimal inhibitory concentration (MIC(90); 0.12 microg/ml) among all agents tested and 99.8% of the isolates were susceptible. For Acinetobacter spp., tigecycline again demonstrated the lowest MIC(90) (2 microg/ml) and the highest percent susceptibility (96.9%). Among Enterobacteriaceae, the 2 most active agents were tigecycline (MIC(90) = 1 microg/ml; 99% susceptible) and imipenem (MIC(90) = 1 microg/ml; 99.5% susceptible). Tigecycline also demonstrated high activity against Streptococcus pneumoniae, Streptococcus pyogenes,Haemophilus influenzae and Enterococcus spp. In summary, tigecycline currently exhibits potent activity against a broad array of bacteria species. Given the dynamics of resistance development, careful monitoring of tigecycline activity against these organisms should remain a significant aspect of ongoing surveillance.
Insights
Tigecycline shows potent activity against a wide range of bacteria, including resistant strains. Ongoing surveillance is crucial to monitor its effectiveness as clinical use grows.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Tigecycline is a key semisynthetic glycylcycline antibiotic.
- Increasing clinical use necessitates baseline data on its efficacy.
- Antimicrobial resistance is a growing global health concern.
Purpose of the Study:
- To establish a baseline for tigecycline's antimicrobial activity.
- To monitor tigecycline's effectiveness against key bacterial pathogens.
- To inform ongoing surveillance strategies.
Main Methods:
- Antimicrobial susceptibility testing was performed.
- Minimal Inhibitory Concentrations (MICs) were determined.
- Isolate susceptibility percentages were calculated.
Main Results:
- Tigecycline demonstrated potent activity against Staphylococcus aureus (MIC(90) = 0.12 µg/ml; 99.8% susceptible).
- High susceptibility rates were observed for Acinetobacter spp. (96.9%) and Enterobacteriaceae (99%).
- Tigecycline was highly active against Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Enterococcus spp.
Conclusions:
- Tigecycline exhibits potent, broad-spectrum activity against diverse bacterial species.
- Current data supports tigecycline's efficacy, but continued monitoring is essential.
- Surveillance is critical to track resistance development and maintain tigecycline's clinical utility.
More Related Videos
05:06Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Related Concept Videos
01:30Development of Antibiotic Resistance
01:25Clinical Significance of Antibiotic Resistance
01:28Antimicrobial Effectiveness